



ten23 health hosts Grand Opening of its State-of-the-Art VIVA2® Sterile Manufacturing Facility in Visp, Switzerland

Basel, Switzerland, September 24, 2024. ten23 health®, a leading Swiss contract development and manufacturing organization (CDMO), yesterday proudly hosted the Grand Opening of its VIVA2® facility in Visp, Switzerland.

The event marks a significant milestone in the company's growth, as the newly constructed VIVA2® facility is one of the most advanced and energy efficient of its kind. It will provide significant capacity for commercial, as well as clinical fill/finish of vials, syringes and cartridges, in combination with dedicated Quality Control microbiology labs and related office space.

The two additional sterile manufacturing lines include Line 2, a large-scale commercial and clinical filling line for ready-to-use (RTU) primary packaging for syringes, cartridges and vials; and Line 3, a clinical to commercial bulk vial filling facility, including two larger-scale freeze driers (lyophilizers). The combined output is estimated to be 30 to 70 million units. ten23's Line 2 is an 8-headed filling machine and scale-up version of Line 1; both lines are based on Class C isolator technology and utilize filling with automated robots, and peristaltic and piston pumps. This enables optimal processing and controls, including 100% fill weight control, and ultra-high fill and stopper setting precision for syringes and cartridges. The technology means that filling is effectively headspace-free, and container-to-container contact is avoided. ten23 can process glass or polymer containers and has experience of processing ultra-viscous formulations such as for subcutaneous or intravitreal use.

Aligned with the company's commitment to sustainability, the pioneering building features a cutting-edge façade fully covered with 1,550 m² of solar (photovoltaic) panels. These panels harness optimal sunlight in summer and benefit from snow and glacier reflections in winter, generating an estimated 100,000 kWh of green electricity annually for the facility.

The expansion will offer employment opportunities in the Valais area, supporting the development of the region as one of the leading pharmaceutical hubs in Switzerland.

At the opening ceremony on Monday 23rd September, ten23 hosted politicians and local administrators as well as representatives of the healthcare industry, collaboration partners and customers. The team shared insights into the advanced technology which is integral to the new facility, allowing highly precise, bubble free and Annex 1 compliant vial and syringe filling, with new end-to-end quality control capabilities.

"I am proud and excited about the VIVA2® Facility Grand Opening. This is the start of something great, and VIVA2's capabilities for sterile manufacturing will be a key opportunity to supply essential medicines to patients," said Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health.



About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.

ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B-Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

Media contacts:

ten23 health: Marija Petrovic, marija.petrovic@ten23.health; +41 78 694 87 33

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021